Not exact matches
McCague says tamandron has a similar structure to
tamoxifen but one part of the molecule resembles testosterone (see Diagram) and this should cause it to
bind specifically to androgen receptors.
Tamoxifen then
binds to the ER - LDB domains of the fusions allowing Cre / FLP translocate to the nucleus where they exert their recombinase activity (Logie and Stewart 1995; Metzger et al. 1995).
As you know,
tamoxifen is a non-steroid, weak - acting estrogen that
binds to estrogen receptors in the breast and supposedly reduces the risk of breast cancer.
In this way,
tamoxifen prevents a women's own estrogen from
binding with these cells.